Larimar Therapeutics, Inc.
NASDAQ:LRMRBiotechnology
+$0.04 today
- Market cap
- $337.45M
- Beta
- 0.82
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.95
Volume 1.41M
Average 1.73M
LRMR Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Larimar Therapeutics, Inc.NASDAQ: LRMR
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses dips below year-ago levels
Q1 FY2026 operating expenses of $31.12M fell 0.2% year over year, behind the +63.7% change in trailing-twelve-month operating expenses. Sequentially, it fell 51.4% from the prior quarter. Over 3 fiscal years it compounded at +67.8% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -0.2% toward the trailing-twelve-month pace of +63.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 172.5M USD
- Year-over-year change
- +89.8%
- 4-year CAGR
- +36.0%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 172.5M | +89.8% |
| FY2024 | 2024-12-31 | 90.89M | +117.7% |
| FY2023 | 2023-12-31 | 41.76M | +14.3% |
| FY2022 | 2022-12-31 | 36.53M | -27.6% |
| FY2021 | 2021-12-31 | 50.47M | — |
Operating Expenses vs competitors
How LRMR compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +63.7% is the highest of 11, against a peer median of -12.8%.
- Over three fiscal years its annual growth of +67.8% compares with a peer median of +14.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $203.15M USD | +11.1% | +13.5% | — | |
| LTM Mar 2026 | $172.43M USD | +63.7% | +67.8% | — | |
| LTM Mar 2026 | $164.05M USD | +44.9% | +13.2% | — | |
| LTM Mar 2026 | $162.92M USD | +24.9% | +67.1% | — | |
| LTM Mar 2026 | $150.13M USD | -11.1% | -27.1% | 69.9% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $132.21M USD | +50.3% | +85.1% | — |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $97.24M USD | -16.4% | +21.3% | — |
| LTM Mar 2026 | $85.57M USD | -14.7% | +14.9% | 2227.3% | |
| LTM Mar 2026 | $81.97M USD | -16.5% | +2.5% | 227697.2% | |
| LTM Mar 2026 | CHF 68.45M CHF | -14.4% | -1.1% | 1849.0% | |
| LTM Mar 2026 | -$55.19M USD | -179.1% | +31.6% | — | |
| Peer median (excluding LRMR) | — | -12.8% | +14.2% | 2038.1% | |
Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 38.4M | 24.25M | 27.67M | 73.28M | 154.22M |
| Selling, General & Admin | 12.07M | 12.28M | 14.09M | 17.61M | 18.27M |
| Operating Expenses | 50.47M | 36.53M | 41.76M | 90.89M | 172.5M |
| Depreciation & Amortization | 326K | 318K | 311K | 318K | 350K |
| EBITDA | (50.31M) | (35.04M) | (36.64M) | (80.29M) | (165.32M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (50.47M) | (36.53M) | (41.76M) | (90.89M) | (172.5M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (171K) | 1.17M | 4.81M | 10.29M | 6.82M |
| Income Before Tax | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.93) | (1.33) | (0.84) | (1.32) | (2.27) |
| EPS (Diluted) | (2.93) | (1.33) | (0.84) | (1.32) | (2.27) |
| Weighted Avg Shares | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
| Weighted Avg Shares (Diluted) | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
Larimar Therapeutics, Inc.
NASDAQ:LRMR
Intrinsic Alpha fair value
Locked
Current Price
$3.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.